Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > April 28, 2023
Daily News
April 28, 2023
- Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
- Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
April 28, 2023
- Trade Group Demands Better Market Environment for Regenerative Medicine, Proposes New Pricing Model
April 28, 2023
- Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
April 28, 2023
- LDP League Calls for Generic Market Entry Rules to Ensure Supply: Draft Proposal
April 28, 2023
- Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
- Astellas to Promote HR Chief Katsuyoshi Sugita to EVP
April 28, 2023
- Taiho’s Futibatinib Nabs EU Panel Backing for Bile Duct Cancer
April 28, 2023
- Chugai Seeks Vabysmo Label Expansion for RVO
April 28, 2023
- 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
- Will Bill to Amend Medical Infrastructure Law Accelerate Drug Discovery for Rare Diseases?
April 28, 2023
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…